From Name:
From Email:
To Name:
To Email:

Optional Message:

Targeted therapy no better than drug alone in advanced renal cell carcinoma

from OncLive

Combination targeted therapy did not significantly extend progression-free survival compared with single-agent bevacizumab in patients with advanced renal cell carcinoma, according to the results of a randomized phase II trial. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063